Eager for more news? Sign up to get more updates about our happenings!
August 2016
EpitoGenesis Publication:
Vitamin A or E and a catechin synergize as vaccine adjuvant to enhance immune responses in mice by induction of early interleukin-15 but not interleukin-1β responses. Patel S, Akalkotkar A, Bivona JJ 3rd, Lee JY, Park YK, Yu M, Colpitts SL, Vajdy M. Immunology. 2016 Aug;148(4):352-62. doi: 10.1111/imm.12614.
July 2015
EpitoGenesis Publication:
Induction of cellular and molecular immunomodulatory pathways by vitamin A and flavonoids. Patel S, Vajdy M.Expert Opin Biol Ther. 2015;15(10):1411-28. doi: 10.1517/14712598.2015.1066331. Review.
September 2014
EpitoGenesis was awarded $225,000 as a Phase I SBIR contract from the National Institutes of Allergy and Infectious Diseases to develop a vaccine against pandemic Influenza.
July 2013
EpitoGenesis Inc. relocated from Walnut Creek, California to Storrs, Connecticut.
July 2013
EpitoGenesis was awarded $800,000 from the State of Connecticut's Office of Economic Development to develop and manufacture the proprietary Nutritive Immune-enhancing Delivery System.
June 2013
EpitoGenesis was awarded a Phase I Advanced Technology STTR grant from the National Institutes of Allergy and Infectious Diseases to develop a vaccine against vaginal transmission of Chlamydia trachomatis, using their proprietary Nutritive Immune-enhancing Delivery System, in collaboration with Dr. Deborah Dean at Children's Hospital Oakland Research Institute. The grant is for two years and the monetary award is $600,000. The second year of this award will be allocated to EpitoGenesis in Connecticut.
November 2011
EpitoGenesis Publication:
Immunomodulatory properties of vitamins, flavonoids and plant oils and their potential as vaccine adjuvants and delivery systems.Vajdy M. Expert Opin Biol Ther. 2011 Nov;11(11):1501-13. doi: 10.1517/14712598.2011.623695. Review.
March 2011
EpitoGenesis Publication:
A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations. Yu M, Vajdy M. Vaccine. 2011 Mar 16;29(13):2429-36. doi: 10.1016/j.vaccine.2011.01.024.
October 2010
The Board of Directors agrees that as of January 1, 2011, Dr. Michael Vajdy will serve as President and CSO, while Ms. Shohre Golestani will serve as the CEO, with equal decision making rights over all matters related to the management of EpitoGenesis, Inc.
October 2010
EpitoGenesis enters into an agreement with Dr. Deborah Dean at Children’s Hospital Oakland Research Institute on a collaborative project to develop a vaccine against sexual transmission of Chlamydia trachomatis.
October 2010
EpitoGenesis, Inc. is awarded an NIH grant to further explore the NIDS technology for HIV vaccines.
October 2010
EpitoGenesis begins collaboration with Dr. Julia Hurwitz at St. Jude’s Hospital on an HIV vaccine project and submission of a collaborative grant to the NIH.
September 2010
Dr. Michael Vajdy is invited as a renowned speaker to participate in the BIT Life Sciences’ 3rd Annual World Vaccine Congress, in Beijing, China.
August 2010
EpitoGenesis Publication:
Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.Yu M, Vajdy M.Expert Opin Biol Ther. 2010 Aug;10(8):1181-95. doi: 10.1517/14712598.2010.496776. Review
August 2010
Dr. Michael Vajdy is invited to give a talk about the NIDS technology at the Novel Vaccines conference in Boston, MA, organized by the Cambridge Healthtech Institute.
June 2010
EpitoGenesis relocated to a new laboratory and office facility at 1810 North Broadway, Walnut Creek, CA 94596.
January 2010
EpitoGenesis acquired preclinical results in murine models demonstrating that the proprietary nutritive immune-enhancing delivery system (NIDS) significantly enhanced immune responses against influenza hemagglutinin and HIV-1 gp120 following mucosal and systemic vaccinations with the same NIDS formulation.
December 2009
EpitoGenesis acquired preclinical results in murine models demonstrating that the proprietary nutritive immune-enhancing delivery system (NIDS) significantly enhanced immune responses against influenza hemagglutinin and HIV-1 gp120 following mucosal and systemic vaccinations with the same NIDS formulation.
May 2009
EpitoGenesis Inc. was awarded a Phase I, Small Business Innovation Research grant from the National Institutes of Health to develop a novel mucosal HIV vaccine.
March 2009
The Scientific Advisory Board was formed.
January 2009
EpitoGenesis Inc. filed an application for an SBIR phase I grant for research and development of a mucosal HIV vaccine.
December 2008
Moved in Laboratory and office space at 112 La Casa Via, suite 160, Walnut Creek, California, across from John Muir Hospital.
November 12, 2008
EpitoGenesis Inc. was incorporated.